PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice

... adenosine Regulation with GP531 Improves the Heart's ... The study entitled "Intravenous GP531, an adenosine Regulating Agent, Improves Left Ventricular ... new class of cardioprotective compounds known as adenosine regulating agents (ARAs). ARAs, including GP531, ...

Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment

... terminate re-entrant PSVT involving the AV node. adenosine is the only approved competition in the U.S. ... of adenosine in terminating PSVT. While ATP and adenosine both inhibit AVN conduction, ATPace(TM) is ... based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These ...

Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)

... -First A2A adenosine Receptor Agonist Approved for Use in Identifying ... of Lexiscan(TM) (regadenoson) injection, an A2A adenosine receptor agonist, for use as a ... Therapeutics (Nasdaq: CVTX ), is the first A2A adenosine receptor agonist shown to be safe and effective ...

Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics

... Lexiscan(TM) (regadenoson) injection, an A2A adenosine receptor agonist, for use as a pharmacologic ... (regadenoson) injection Lexiscan(TM) is an A2A adenosine receptor agonist approved for use as ... coronary blood flow by activation of the A2A adenosine receptor. Lexiscan(TM) is administered as a rapid ...

CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection

... Lexiscan(TM) (regadenoson) injection, an A2A adenosine receptor agonist, for use as a pharmacologic ... The product has been designed to target the A2A adenosine receptor, which is the adenosine receptor subtype responsible for coronary ...

CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection

... -First A2A adenosine Receptor Agonist Approved for Use as ... (regadenoson) injection, an A2A adenosine receptor agonist, for use as a pharmacologic ... exercise stress. Lexiscan is the first A2A adenosine receptor agonist shown to be safe and effective ...

PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation

... patients. Adenosine-Mediated Cardioprotection adenosine regulation by acadesine provides highly site- ... the drug in controlled clinical trials. adenosine targets a broad-spectrum of the pathophysiology ... types than was recognized only ten years ago. adenosine has been shown to be a powerful mediator of ...

Cordex Completes Production of ATPace(TM) Clinical Trial Material

... ATPace(TM) is a novel, proprietary, stable, injectable formulation of adenosine 5'-triphosphate (ATP) under development as a therapeutic and diagnostic ... new cardiovascular medicines based upon the emerging pharmacology of adenosine 5'-triphosphate (ATP) and nitric oxide (NO). These two molecules play ...

Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine

... with a genetic defect that leaves them unable to produce an enzyme called adenosine deaminase. This key enzyme is most active in lymphocytes, which are white ... on the success of a DNA-based approach for the introduction of a normal adenosine deaminase gene into the patient's hematopoietic stem cells that have been ...

Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results

... in Greenville, NC. ATPace, a stable liquid formulation of adenosine 5'-triphosphate (ATP) for intravenous injection, is an ... -- Acquisition of exclusive worldwide rights for ATPotent, a novel adenosine 5'-triphosphate (ATP)-based sperm-processing medium designed to ...

CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases

... Company's investigational new drug application for CVT-3619, a partial A1 adenosine receptor agonist. This Phase 1 trial will assess the safety and ... program to complement our two approved products." CVT-3619 binds to the adenosine A1 receptor on fat cells, called adipocytes, potentially leading to a ...

Schering-Plough Reports Financial Results for 2009 Second Quarter

... disorder; Initiation of patient enrollment in a Phase III trial (RED-CABG) in May for acadesine, an investigational, potentially first-in-class adenosine regulating agent for use in heart bypass surgery; and In Animal Health, the launch of the first vaccine against canine influenza virus, which ...

Serial Monitoring With ImmuKnow(R) is Useful in the Risk Assessment of Kidney Transplant Recipients

... that assesses cellular immune status by detecting cell-mediated immunity (CMI) in adult immunosuppressed patients. It measures the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation. The ImmuKnow test is a qualitative assay and does not directly quantify the ...

Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial

... with acute coronary syndrome undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in ...

European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI

... the tendency of platelets, the blood particles responsible for clotting, from sticking or clumping together. By blocking a specific receptor (P2Y12 adenosine diphosphate) on the platelet surface, prasugrel prevents platelets from clumping, which can result in clogged arteries and may lead to heart attack. ...

Cordex Pharma Forms Heart Failure Medical Advisory Board

... Pharma, Inc. Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation ...

Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29

... Pharma, Inc. Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation ...

Researchers: Molecular forklifts overcome obstacle to 'smart dust'

... telltale indicator of the contaminant. The process requires no rinsing. And instead of electricity, the naturally derived forklifts are powered by adenosine triphosphate, or ATP, the molecule that carries energy for cells. "You have replaced all this washing with this active transport by molecular ...

You: Being Beautiful Authors Mehmet Oz, MD, & Michael Roizen, MD, Call Ribose One of the Decade's 'Real Nutritional Heroes'

... that can "turbo-charge" those who need an energy boost. Ribose is a naturally occurring 5-carbon sugar the body uses to stimulate the production of adenosine triphosphate (ATP) -- an essential energy compound. Although ribose is produced by the body, this energy molecule cannot be replenished fast ...

New Report Provides Expert Analysis of Recent Advances and Setbacks in Parkinson's Disease Drug Development

... alpha-synuclein; -- Dopamine agonists, monoamine oxidase inhibitors; -- Levodopa formulations, COMT inhibitors; and -- adenosine A2A receptor antagonists, cholinesterase inhibitors, AMPA, 5-HT, anticonvulsants, antihypertensives, farnesyl transferase inhibitors. ...

Bioenergy D-Ribose Achieves Highest Safety Standard

... and Drug Administration (FDA) for its core energy nutrient D-ribose, a naturally occurring monosaccharide the body uses to stimulate the synthesis of adenosine triphosphate (ATP) -- an essential energy compound. "The FDA's written response that it has reviewed the submitted safety evidence and has no ...

Celsis Launches RapiScreen(TM) Beverage Microbial Screening System

... the same trusted platform now can be used to test for contamination across their entire spectrum of products, quickly and efficiently." adenosine Triphosphate (ATP) bioluminescence is the industry standard for the rapid microbial screening of UHT and ESL beverage products. Using proprietary ...

Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant

... Inc. (Duska) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of ...

CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2008

... And Reperfusion; Poster Presentation, Monday, November 10, 2008, 3:00 p.m. CST Lexiscan(R) (regadenoson) injection High Reproducibility of Serial adenosine Single Photon Tomography Myocardial Perfusion Studies: A Quantitative Analysis from the ADVANCE 2 Study; Poster Presentation, Sunday, November 9, ...

Cylex(TM) Receives ISO 13485:2003 and 9001:2000 Quality Certifications

... immunity (CMI) in adult patient populations undergoing immunosuppressive therapy for organ transplantation by measuring the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation. The ImmuKnow test is a qualitative assay and does not directly quantify the ...

Duska Therapeutics to Present at Noble Financial Equity 'M.A.D. MAX' Conference on Tuesday, August 19th at 1:30 p.m. PDT

... Inc. (Duska) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of ...

Raj Khankari Named Bioenergy, Inc., CEO

... related to the enhancement of blood components. D-Ribose is a naturally occurring monosaccharide the body uses to stimulate the synthesis of adenosine triphosphate (ATP), an essential energy compound. ATP is critical to health and maintaining normal energy-dependent body functions. Ribose is an ...

Novel compound may treat acute diarrhea

... "This newly discovered compound decreases the formation of ever-present cellular messenger molecules, cyclic guanosine monophosphate and cyclic adenosine monophosphate, caused by various bacterial toxins and might prevent or attenuate the intestinal fluid secretion, diarrhea and dehydration," said ...

D-Ribose Helps Energy-Starved Hearts

... will benefit from Corvalen(R) D-ribose because it addresses the 'energy crisis' at the cellular level. "Corvalen(R) stimulates the synthesis of adenosine triphosphate (ATP), an essential energy compound found in every cell in the body," explains Dr. Vagnini, author of Count Down Your Age (McGraw-Hill, ...

Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection

... is an immune cell function assay that can detect cell-mediated immunity (CMI) in adult immunosuppressed patients by measuring the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation. The ImmuKnow test is a qualitative assay and does not directly quantify the ...

Sagent Pharmaceuticals Launches Cefazolin for Injection, USP

... for injection follows Sagent's December 2007 introduction of the first full-line of latex-free, multi-source prefilled, ready-to-use, 6 mg and 12 mg, adenosine syringes in the market. Sagent will begin marketing and shipping Cefazolin immediately. "The launch of Cefazolin, the first product to emerge from ...

Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002)

... discussion to determine a path forward for istradefylline (KW-6002). Istradefylline (KW-6002) has a novel mechanism of action that antagonizes the adenosine A2A receptor. It has been under FDA review as adjunctive therapy to levodopa/carbidopa for the treatment of idiopathic Parkinson's disease to improve ...

CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session

... Double-blind, Placebo-controlled MERLIN-TIMI 36 Trial; Poster, Tuesday, April 1, 2008, 11:00 a.m. CST Regadenoson Heart Rate Response to adenosine and Regadenoson in Diabetes Mellitus: A Marker of Autonomic Cardiac Neuropathy; Poster, Tuesday, April 1, 2008, 11:30 a.m. CST Additional ...

PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors

... Inc. is a privately-held specialty biopharmaceutical company focused on the development and commercialization of a new class of medicines, adenosine regulating agents, to prevent the perioperative complications of surgery and improve the treatment and outcomes of acute cardiovascular care. ...

Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration

... acute coronary syndrome who are managed with PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in ...

CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007

... in the MERLIN TIMI-36 Trial; Poster, Wednesday, November 7, 2007, 9:30 - 11:00 a.m. EST Tecadenoson Ventricular Rate Control Using the adenosine Receptor Agonist CVT 510 in the Goat Model of Atrial Fibrillation: Efficacy During Exercise and Synergistic Effects with Metoprolol; Oral abstract, ...

Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System

... (Sigma A-7699) adenosine monophosphate (AMP) (Sigma A-2002) ... 3-fold increase in activation of the enzyme in the presence of adenosine 5’-monophosphate (AMP).

† Other pack sizes ...

ATP Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #40)

... Evelyn McGown, Ph.D. and Michael Su, M.S. Molecular Devices Corporation, 8/00 INTRODUCTION adenosine triphosphate (ATP) is present in all living cells. Because the level isstrictly-controlled, assay of ATP can be used as a indicator of viable cell ...

cAMP DataFile: Homogenous Cyclic AMP detection using High Efficiency Fluorescence Polarization

... Requires no separation or wash steps Available in a kit and in bulk packaging Introduction Cyclic adenosine monophosphate (cAMP) is a second messenger involved in the transduction of extracellular signals. The signal is initiated by the binding of a ligand ...